Nurix Therapeutics (NRIX) Expected to Announce Quarterly Earnings on Tuesday

Nurix Therapeutics (NASDAQ:NRIX) is expected to post its Q1 2026 results before the market opens on Tuesday, April 14th. Analysts expect Nurix Therapeutics to post earnings of ($0.76) per share and revenue of $14.2530 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, April 17, 2026 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. The company had revenue of $13.58 million for the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $15.79 on Tuesday. The firm has a market capitalization of $1.63 billion, a P/E ratio of -5.19 and a beta of 1.97. Nurix Therapeutics has a one year low of $8.18 and a one year high of $22.50. The company’s fifty day moving average is $15.83 and its two-hundred day moving average is $15.16.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and set a $26.00 target price on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Mizuho boosted their target price on shares of Nurix Therapeutics from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Morgan Stanley set a $36.00 target price on shares of Nurix Therapeutics and gave the stock an “overweight” rating in a research report on Thursday, January 8th. Stifel Nicolaus boosted their target price on shares of Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Finally, BTIG Research restated a “buy” rating and set a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.54.

Insider Activity

In related news, insider Gwenn Hansen sold 4,895 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the sale, the insider directly owned 83,672 shares in the company, valued at $1,388,955.20. The trade was a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NRIX. Morgan Stanley boosted its position in shares of Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock worth $92,594,000 after buying an additional 2,620,323 shares in the last quarter. Rubric Capital Management LP purchased a new stake in shares of Nurix Therapeutics in the 4th quarter worth about $46,930,000. Braidwell LP purchased a new stake in shares of Nurix Therapeutics in the 4th quarter worth about $41,428,000. Price T Rowe Associates Inc. MD boosted its position in shares of Nurix Therapeutics by 195.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock worth $61,622,000 after buying an additional 2,149,268 shares in the last quarter. Finally, Vestal Point Capital LP boosted its position in shares of Nurix Therapeutics by 73.8% in the 3rd quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock worth $32,109,000 after buying an additional 1,475,000 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.